Latest Market Launch News

Page 2 of 10
OncoSil Medical reported a 53% increase in unit sales and advanced key regulatory approvals, including FDA final review and TGA listing, positioning it for growth in pancreatic cancer treatment.
Ada Torres
Ada Torres
30 July 2026
Cleo Diagnostics has entered the critical Analytical Validation phase for its ovarian cancer blood test, progressing toward an FDA 510(k) submission targeted for the first half of 2027. The company also secured a U.S. reimbursement pathway to support early market entry post-clearance, backed by a cash balance of A$6.2 million.
Ada Torres
Ada Torres
29 July 2026
IKE GPS delivered a 31% jump in subscription revenue exit run rate in 1Q FY27, with three new products and an AI platform set to fuel further growth in the second half.
Sophie Babbage
Sophie Babbage
29 July 2026
Mesoblast has completed treatment of 300 patients in its pivotal Phase 3 trial for rexlemestrocel-L, targeting chronic low back pain due to degenerative disc disease, with topline results expected mid-2027.
Ada Torres
Ada Torres
14 July 2026
Orthocell Limited has posted record revenue for FY2026, driven by strong sales growth of Remplir™ and Striate+™ products in Australia, the US, and new international markets, supported by a robust $44.1 million cash position.
Ada Torres
Ada Torres
13 July 2026
Neurizon Therapeutics has secured a critical five-year supply agreement with Elanco Animal Health for GMP-grade monepantel, underpinning the commercialisation readiness of its lead ALS drug candidate NUZ-001.
Ada Torres
Ada Torres
17 June 2026
Ovanti Limited has inked a four-year exclusive partnership with Yuno.trade, positioning itself as the payment processor and technology backbone for a new licensed prediction market platform targeting Southeast and Central Asia.
Victor Sage
Victor Sage
9 June 2026
Acrux has amended its licensing agreement with Gedeon Richter to bring its Estradiol spray Lenzetto® to Australia, unlocking up to AUD 5.4 million in milestone payments and addressing a critical shortage in Menopause Hormone Therapy products.
Ada Torres
Ada Torres
28 May 2026
Aroa Biosurgery posted a breakout FY26, beating revenue and EBITDA guidance with a 54% surge in Myriad sales. The company plans significant investments in FY27 to accelerate growth and capitalise on new market opportunities.
Ada Torres
Ada Torres
26 May 2026
Eden Innovations appoints former European Parliament member Antanas Guoga to lead EdenShield’s push into European defence and critical infrastructure markets amid surging regional security spending.
Victor Sage
Victor Sage
21 May 2026
Cleo Diagnostics has laid out a clear U.S. reimbursement pathway for its ovarian cancer test, leveraging an existing CPT code to enable early market entry and data collection ahead of FDA clearance.
Ada Torres
Ada Torres
20 May 2026
Biome Australia’s Activated Probiotics brand surpasses one million boxes sold in Australia, approaches top pharmacy ranking, and launches nationally in Canada, setting the stage for FY26 profitability.
Ada Torres
Ada Torres
28 Apr 2026

Browse the archive

Full archive